Obesity represents an escalating global public health concern, necessitating the development and implementation of new, more effective intervention strategies. Ongoing research into novel pharmacological treatments for obesity is yielding promising results. The latest advancement in this field is retatrutide, a triple agonist targeting the receptors for glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. This study aims to provide a detailed analysis of the safety profile of retatrutide based on data from available phase I and II clinical trials. Retatrutide demonstrated a favorable safety profile, with gastrointestinal symptoms being the most commonly reported adverse effects. These preliminary findings are promising and warrant further investigation. Although the results are encouraging, further research is needed to elucidate the mechanisms of action of triple agonists and assess their longterm efficacy. Such studies will be crucial for guiding personalized therapeutic strategies and optimizing their clinical utility across various patient groups.